$VNDA News

Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches

Vanda puts anxiety drug’s development on ice after Phase III fail

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis

Vanda (VNDA) Q2 2026 Earnings Call Transcript

B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12